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Abstract
Background: Biological interpretation of genomic summary data such as those resulting from genome-wide
association studies (GWAS) and expression quantitative trait loci (eQTL) studies is one of the major bottlenecks in
medical genomics research, calling for efficient and integrative tools to resolve this problem.
Results: We introduce eXploring Genomic Relations (XGR), an open source tool designed for enhanced interpretation
of genomic summary data enabling downstream knowledge discovery. Targeting users of varying computational skills,
XGR utilises prior biological knowledge and relationships in a highly integrated but easily accessible way to make
user-input genomic summary datasets more interpretable. We show how by incorporating ontology, annotation, and
systems biology network-driven approaches, XGR generates more informative results than conventional analyses. We
apply XGR to GWAS and eQTL summary data to explore the genomic landscape of the activated innate immune
response and common immunological diseases. We provide genomic evidence for a disease taxonomy supporting the
concept of a disease spectrum from autoimmune to autoinflammatory disorders. We also show how XGR can define
SNP-modulated gene networks and pathways that are shared and distinct between diseases, how it achieves
functional, phenotypic and epigenomic annotations of genes and variants, and how it enables exploring
annotation-based relationships between genetic variants.
Conclusions: XGR provides a single integrated solution to enhance interpretation of genomic summary data
for downstream biological discovery. XGR is released as both an R package and a web-app, freely available at
http://galahad.well.ox.ac.uk/XGR.
Keywords: Software, eXploring Genomic Relations, Genomic summary data, Enhanced interpretation, Network
analysis, Enrichment analysis, Similarity analysis, Annotation analysis
Background
One of the defining characteristics of medical genomics
research is the large volume of genomic data available
but the comparatively limited amount of biological
knowledge revealed. This ‘big-data-limited-knowledge’
discrepancy stems from the heterogeneous forms and
handling of raw data (usually unstructured), but is also
attributed to imprecision in downstream interpretation
[1, 2]. Data ready for downstream interpretation can be
conveniently expressed as ‘genomic summary data’; that
is, a list of genes or SNPs (or, more generally, genomic
regions) along with summary statistics regarding the
significance level (e.g. p values).
Using genomic summary data as a starting point for
knowledge discovery is appealing. Cases in point are
genome-wide association studies (GWAS) producing
summary data on disease-associated genetic variants
(GWAS SNPs) and expression quantitative trait loci
(eQTL) mapping producing summary data on expression-
associated genetic variants (eQTL SNPs). Firstly, it simpli-
fies raw data (usually complex) and captures the essential
information content. Secondly, GWAS and eQTL sum-
mary data are publicly available and well curated in
relational databases, such as the GWAS Catalog [3],
ImmunoBase [4], GTEx Portal [5], and Blood eQTL
browser [6]. By comparison, the limited availability of
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genotyping data makes it prohibitively hard for ordinary
users to conduct cross-disease and cross-study analyses,
particularly those involving multiple data providers.
Thirdly, cross-disease GWAS summary data hold great
promise in understanding the genetic basis of disease co-
morbidity [7], whilst eQTL summary data could be useful
in identifying genetic targets for drug development [8, 9].
Despite the availability and potential utility of this
summary data, precise knowledge discovery itself is not
trivial. It raises two critical issues: first, how to more
systematically use widely distributed knowledge about
genes and SNPs, much of which is unfortunately re-
corded in natural language; and second, how to achieve
insights at the gene network level, which is desirable
considering the interdependent and often synergistic
nature of biological systems involving multiple players to
complete the same task.
Knowledge use and access via ontologies provides an
effective and efficient solution to the first issue. Using
ontologies to annotate genes and gene products dates
back to the beginning of this century when the Gene
Ontology (GO) consortium initiated efforts to digitise
gene functions [10]. Since then, a number of ontologies
have been created to describe genes from the perspective
of other knowledge domains (e.g. diseases [11] and phe-
notypes [12, 13]) and to describe protein domains [14].
Recent years have seen the shift in focus from the gene
level to the SNP level (and generally to the genomic
region level), accelerated by efforts to understand regu-
latory variants that most commonly underlie GWAS
[15], resulting in the generation of increasing amounts
of functional genomic data [16]. Compared to coding
genes, which are well annotated by ontologies, non-
coding genomic regions are lacking such annotations.
Their interpretation relies heavily on either extrapolation
from nearby genes or functional genomic data generated
experimentally by large consortia such as ENCODE [17],
FANTOM5 [18], BLUEPRINT Epigenome [19], TCGA
[20], and Roadmap Epigenomics [21].
To address the second issue, gene interaction data
should ideally be generated experimentally for every
tissue, in both normal and diseased conditions given the
fact that gene interactions are highly context-specific. In
reality, an achievable alternative to this is to assimilate
available context-specific interactions into a less context-
specific, so-called ‘ground-truth gene network’ representing
unified interaction knowledge. This strategy can be seen in
databases such as STRING [22] and Pathway Commons
[23]. Acting as a ‘scaffold’, the ground-truth gene network
can then be integrated with context-specific summary data
to identify the subset of the gene network, or ‘gene subnet-
work’, that best explains that data.
The above issues identify an emerging need for ‘enhanced
interpretation’ (effectiveness, efficiency, and transparency),
particularly at the SNP and genomic region level. To
meet this need, and also within our vision of its general
use in eXploring Genomic Relations, we develop the
open-source software ‘XGR’ for enhancing knowledge
discovery from genomic summary data. In addition to its
comprehensive use of ontology and network informa-
tion, we also show the uniqueness of XGR in 1)
ontology tree-aware enrichment and similarity analysis
and 2) cross-disease network and annotation analysis.
Using real datasets [4, 24], we showcase its analytic power
in uncovering the genetic landscape of immunological
disorders based on GWAS summary data, and also dem-
onstrate its added value in interpreting eQTL summary
data of an immune-activated system. In short, XGR is
software designed for enhanced interpretation necessary
for doing big data science in genomics.
Implementation
Overview
Figure 1 gives an overview of what XGR is and what the
user can expect from it. XGR has two ends, the backend
(an R package) [25] and the frontend (a web-app) [26].
Metaphorically, it works as a knowledge-driven ‘mega-
bus’, carrying the passengers (users of varying computa-
tional skills) from the departure (a user-input list of
genes, SNPs, or genomic regions) to the destination
(outputs in a user-friendly format including ontology
enrichments and network relationships). The petrol used
by this megabus is the ontology and network knowledge
(see next section), and the engine is its analytical
capability, currently supporting enrichment, similarity,
network, and annotation analysis (summarised in Table 1;
see below for details). Put simply, XGR is designed to
interpret genomic summary data resulting from modern
genetic studies (differential expression, GWAS, and
eQTL mappings), not targeting the upstream generation
of summary data but instead enhancing its downstream
biological discovery.
Source data and uniform representations
As a central part of the knowledge-driven interpretations,
we have assembled currently available knowledge at the
gene, SNP, and genomic region level (detailed below). All
source data are represented uniformly as well-documented
RData-formatted files, taking advantage of the R software
open-development environment and its infrastructure
packages such as igraph [27] and GenomicRanges
[28]. The primary source data are maintained as part
of in-house relational databases, from which Perl
scripts are used to create RData files. Following an
established pipeline, they are subject to regular up-
dates and are also regularly supplemented to keep
pace with the explosive nature of big data in
genomics.



























enrichments (bar/DAG plots) 
(Fig. 2, 7, 8)
cross-disease information 
(Fig. 3)
network relations (Fig. 4)
annotations (Fig. 5, 6)
similarity (circos/DAG plots) 
(Fig. 9)
Regions
Fig. 1 Schematic workflow of XGR: achieving enhanced interpretation of genomic summary data. This flowchart illustrates the basic concepts
behind XGR. The user provides an input list of either genes, SNPs, or genomic regions, along with their significance levels (collectively referred to
as genomic summary data). XGR, available as both an R package and a web-app, is then able to run enrichment, network, similarity, and annotation
analyses based on this input. The analyses themselves are run using a combination of ontologies, gene networks, gene/SNP annotations,
and genomic annotation data (built-in data). The output comes in various forms, including bar plots, directed acyclic graphs (DAG), circos plots, and
network relationships. Furthermore, the web-app version provides interactive tables, downloadable files, and other visuals (e.g. heatmaps)
Table 1 A summary of XGR characteristics for tasks achieved and runtime required
Functions Tasks achieved Runtimea
Enrichment analysis
xEnricher A template for enrichment analysis ~40
xEnricherGenes Gene-based enrichment analysis using a wide variety of ontologiesb ~40
xEnricherSNPs SNP-based enrichment analysis using Experimental Factor Ontology on GWAS traits ~70
xEnricherYours Custom-based enrichment analysis using user-defined ontologies ~5
xEnrichConciser Removing redundant ones from enrichment outputs ~15
xEnrichBarplot Barplot of enrichment outputs <1
xEnrichCompare Side-by-side barplots of comparative enrichment outputs <1
xEnrichDAGplot DAG plot of enrichment outputs <1
xEnrichDAGplotAdv DAG plot of comparative enrichment outputs <1
Annotation analysis
xGRviaGeneAnno Annotation analysis using nearby gene annotations by a wide variety of ontologiesb ~60
xGRviaGenomicAnno Annotation analysis using a wide variety of genomic annotationsc ~30
Similarity analysis
xSocialiser A template for similarity analysis ~60
xSocialiserGenes Gene-based similarity analysis using structured ontologies on functions, diseases, and phenotypes ~70
xSocialiserSNPs SNP-based similarity analysis using Experimental Factor Ontology on GWAS traits ~60
xCircos Circos plot of similarity outputs ~10
xSocialiserDAGplot DAG plot of one set of terms used for similarity analysis <1
xSocialiserDAGplotAdv DAG plot of two sets of terms used for similarity analysis <1
Network analysis
xSubneterGenes Gene-based network analysis ~60
xSubneterSNPs SNP-based network analysis ~60
xVisNet Network visualisation <1
aRuntime (measured by seconds) tested using one core on Mac OS X
bIncluding structured ontologies on functions, diseases, and phenotypes, and non-structured ontologies on pathways, regulatory/expression signatures, druggability,
structural domains, GTEx eGene tissues, others
cIncluding genomic annotations sourced from ENCODE, FANTOME5, BLUEPRINT Epigenome, Roadmap Epigenomics, The Cancer Genome Atlas, UCSC, others
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Ontologies and annotations at the gene level
Conceptually similar to a dictionary, an ontology contains
well-defined vocabularies (called ‘terms’) and their rela-
tionships to each other, and is readable by both humans
and computers. Depending on how relationships between
terms are organised, ontologies can be broadly categorised
into two types: 1) structured ontologies, where terms are
organised in a tree-like structure (specifically a directed
acyclic graph (DAG)), e.g. Gene Ontology [10], Disease
Ontology [11], Phenotype Ontologies in human and
mouse [12, 13]; 2) non-structured ontologies, where terms
are simply listed as keywords, such as a collection of path-
ways from MSigDB [29], and of gene druggable categories
from DGIdb [30]. Using ontologies to annotate genes is
one of the most effective and scalable ways of capturing a
particular knowledge sphere. The reuse of existing know-
ledge through ontology annotations is one of the key
principles behind XGR. At the time of writing (October
2016), XGR supports nearly 30 gene annotations covering
almost every type of knowledge domain, ranging from
functions to diseases, phenotypes, pathways, and many
others (Table 1). Whether structured or non-structured
(in which case an artificial root is created to link together
all terms), an ontology together with annotations is
universally represented as an annotated directed graph.
This design aids in performing operations such as graph
visualisation, annotation propagation (according to the
true-path rule), and semantic similarity calculations be-
tween terms. Ontologies and their identifier codes used in
XGR are summarised in [31].
Ontology annotations at the SNP level
SNP annotations are based on the Experimental Factor
Ontology (EFO). EFO standardises GWAS traits from
the NHGRI GWAS Catalog using well-defined terms [3].
SNPs associated with one or more related traits grouped
together by an EFO term are annotated by this term.
Like any structured ontology, EFO is organised as a
DAG. By the true-path rule, an SNP associated with a
trait (mapped to an EFO term) should also be annotated
by its ancestor terms (more general terms). For example,
SNPs annotated by a term ‘EFO:0000540’ (immune sys-
tem disease) consist of: 1) SNPs directly annotated with
this term; and 2) SNPs associated with its child terms
such as ‘EFO:0005140’ (autoimmune disease) and
‘EFO:0000706’ (spondyloarthropathy), which inherit the
parent annotation. The problem of linkage disequilibrium
(LD) makes it necessary to also include additional SNPs
that are in strong LD with GWAS lead SNPs. For ease use
in XGR, LD SNPs are pre-calculated using PLINK [32]
based on the 1000 Genomes Project data [33] in different
population panels, and those with R2 > 0.8 with GWAS
lead SNPs are retained.
Annotations at the genomic region level
Unlike coding genes that are well annotated using ontol-
ogies, non-coding genomic regions lack such annotations.
Interpretation of these regions relies largely on functional
genomic data generated experimentally and on compara-
tive genomic data predicted by computational methods.
Genomic annotations currently supported in XGR include
a broad spectrum of genomic and epigenomic data includ-
ing, transcription factor binding sites, DNaseI hypersensi-
tivity sites, histone modifications, expressed enhancers,
and genome segmentations (Table 1). Each genomic anno-
tation set is represented as a ‘GRanges’ object, primarily
based on the ‘hg19’ (GRCh37) genome build. Also sup-
ported is conversion of genomic regions between com-
monly used builds: ‘hg19’, ‘hg38’ (GRCh38), and ‘hg18’.
Data types, sources, and identifier codes used in XGR are
summarised in [31].
Interaction networks at the gene level
XGR supports networks of different interaction types
(functional, physical, and pathway-derived), of varying
interaction quality (highest, high, and medium), and of
two interaction directions (directed versus undirected).
Networks are mainly sourced from the STRING data-
base [22] and the Pathway Commons database [23].
STRING is a meta-integration of undirected interactions
from a functional aspect, while Pathway Commons
contains both undirected and directed interactions from
a physical and pathway aspect. Interaction type and
quality, as well as identifier codes used in XGR, are
summarised in [31].
Enrichment analysis
Enrichment analysis (or ‘Enricher’) is based on conven-
tional statistical tests (Fisher’s exact test, hypergeometric
or binomial test) to identify enriched ontology terms
using either built-in or custom ontologies. The Fisher’s
exact test establishes the independence between, for ex-
ample, a user-defined gene group and a group of genes
annotated by a term, and compares sampling only to the
left part of the null background (without replacement).
The hypergeometric test is to sample at random (with-
out replacement) from the null background containing
annotated and non-annotated genes. Finally, and in con-
trast to the hypergeometric test, the binomial test is to
sample at random (with replacement) from the null
background with the constant probability. As to the ease
of reporting the significance level of a term (Additional
file 1), they are, in order: hypergeometric test > Fisher’s
exact test > binomial test. In other words, in terms of the
calculated p value, hypergeometric test < Fisher’s exact
test < binomial test. To further investigate the property
of the statistical test, we simulated a random set of genes
(having the same number of genes as in the real data)
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and estimated how often each enriched term in the real
data would be expected from a null distribution based
on the simulated data. As seen in Additional file 2, the
chance (false positive rate) of enrichments in the real
data that is falsely called significant from the simulated
null data is extremely low. We also assessed false posi-
tive rate by simulating a random set of genes of different
sizes and found they were independent of the size of
gene sets (Additional file 3).
XGR is unique in being designed to produce much
more informative enrichment results. This is achieved
either by taking into account the ontology tree-like
structure when using a structured ontology or by apply-
ing a filtering procedure when using a non-structured
ontology (Fig. 2).
Using a structured ontology
The basic idea is to account for the dependency of terms
during enrichment analysis; for example, estimating the
significance of a term after removing gene annotations
that its significant child terms have. For technical details,
please refer to publications [34, 35].
Using a non-structured ontology
A filtering procedure is applied to further remove redun-
dant terms resulting from enrichment analysis. Take
pathway enrichment analysis as an example (Fig. 2),
assuming that there are two significant pathways, A
and B, and that pathway A is more significantly
enriched than pathway B. The less significant pathway
B is deemed to be redundant if it meets both of the
following criteria: 1) >90% of input genes annotated
with pathway B are also annotated by pathway A; and
2) >50% of input genes annotated by pathway A are
also annotated by pathway B. Both criteria were
chosen empirically, as we observed that the increase
in criterion 1 (90%) would result in the inability to
remove redundant terms (Additional file 4a) and that
criterion 2 (50%) produces the relative stability of re-
dundant terms being removed (Additional file 4b). It
should be noted that, although these default criteria
should be applicable in most circumstances, the user
can refine them by manipulating different thresholds.
Functionality
The function ‘xEnricherGenes’ conducts gene-level en-
richment analysis using either structured ontologies or
non-structured ontologies. The function ‘xEnricherSNPs’
conducts EFO-based enrichment analysis at the SNP
level, allowing the inclusion of additional SNPs that
are in LD with input SNPs. The function ‘xEnricherYours’
enables customised analysis using the user’s own ontol-
ogies and annotations for entities beyond genes and SNPs.
Enrichment outputs are stored as an object of a newly
defined class ‘eTerm’. Directly operating on this object,
the function ‘xEnrichBarplot’ visualises enrichment results
using a barplot, and the function ‘xEnrichDAGplot’ uses a
DAG plot to display enriched terms in the context of the
ontology tree. The function ‘xEnrichCompare’ is specially
designed for side-by-side barplot comparison when in-
volving two or more enrichment results (e.g. across differ-
ent conditions but using the same ontology). The function
‘xEnrichDAGplotAdv’ takes this comparison further,
highlighting which terms are shared and which are unique
in the ontology tree.
Annotation analysis
Annotation analysis (or ‘Annotator’) aims to interpret
a list of user-defined genomic regions in two ways:
either via annotations of nearby genes by ontologies
or via co-localised functional genomic annotations.
Thanks to the diversity of source data available and
the generalisation of data representation (see above),
XGR enables multifaceted interpretation of poorly
annotated genomic regions.
Functionality
The function ‘xGRviaGeneAnno’ takes as input a list of
user-defined genomic regions, defines the nearest genes
within a user-specified distance gap, and conducts en-
richment analysis using nearby gene annotations. Similar
to enrichment analysis at the gene level, this function gives
the choice of structured and non-structured ontol-
ogies, producing informative enrichment results that
can be visually displayed/compared. Alternatively,
both functions ‘xGRviaGenomicAnno’ and ‘xGRvia-
GenomicAnnoAdv’ conduct region-based enrichment
analysis using co-localising functional genomic anno-
tations. The function ‘xGRviaGenomicAnno’ uses the
binomial test for estimating the significance of over-
laps at base resolution. The function ‘xGRviaGenomi-
cAnnoAdv’ estimates the significance of the observed
overlaps against the expectation under the null distri-
bution, which is generated through random sampling
from background genomic regions. By default, the back-
ground uses annotatable genomic regions (depending on
which genomic annotations are used). However, it is
advisable for the user to specify this background ac-
cording to experimental settings. Enrichment results
(as ‘eTerm’ objects) from annotation analysis can be
visualised and compared using functions ‘xEnrichBar-
plot’ and ‘xEnrichCompare’.
Similarity analysis
Similarity analysis (or ‘Socialiser’) calculates semantic
similarity between two genes (or between two SNPs)
based on their ontology annotation profiles. More pre-
cisely, it assesses the degree of relatedness in meaning of




Fig. 2 Necessity of respecting ontology tree-like structure and of removing redundant non-structured pathways in enrichment analysis. This is
demonstrated by analysing differentially expressed genes induced by 24-h interferon gamma in monocytes. The effect of taking ontology tree-like
structure into account is demonstrated using Disease Ontology (DO) and the removal of redundant non-structured ontologies using Reactome
pathways. a Side-by-side bar plots comparing the significant DO terms between the analysis without considering the tree structure (DO Tree(-)) versus
the analysis considering the tree structure (DO Tree(+)). The horizontal dotted line separates commonly identified terms (top section) and redundant
terms in the DO Tree(-) analysis. b DAG plot comparing commonly identified terms (coloured in cyan) and redundant terms from the DO Tree(-) analysis
(coloured in light cyan). The term name (if significant) is prefixed in the form ‘x1-x2’. x1 represents ‘DO Tree (-)’ and x2 ‘DO Tree (+)’. The value of x1
(or x2) can be ‘1’ or ‘0’, denoting whether this term is identified (present) or not (absent). c The top pathway enrichments, with the redundant pathways
to be removed indicated (X). d Illustrations of whether a less significant pathway B is redundant considering a more significant pathway A. Pathway B is
counted redundant if it meets both criteria. Criterion 1: more than 90% of input genes annotated with pathway B are also covered by pathway A.
Criterion 2: more than 50% of input genes annotated with pathway A are also covered by pathway B. Scenario 1 does not meet either criteria, scenario 2
meets both, and scenario 3 meets criterion 1 but not criterion 2. Notably, criterion 2 ensures the resulting pathways (as shown in scenario 3) are
informative in capturing knowledge spheres of different granularities; otherwise, pathway B would be considered redundant in scenario 3, leading to loss
of information. FDR: false discovery rate
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annotation profiles from a structured ontology. The
function ‘xSocialiserGenes’ conducts similarity analysis
for genes using annotations by structured ontologies,
while the function ‘xSocialiserSNPs’ conducts SNP-based
similarity analysis using annotations from EFO.
SNP semantic similarity
The procedure used to calculate semantic similarity
between two SNPs is as follows. First, the information
content (IC) of a term is defined to measure how inform-
ative it is when used to annotate SNPs: –log10(frequency
of SNPs annotated by this term). Semantic similarity be-
tween each pair of terms is pre-calculated, usually quanti-
fied as IC at the most informative common ancestor
(MICA) of the two terms. Finally, semantic similarity
SIM(S1, S2) between two SNPs, S1 and S2, is derived from
pairwise term similarity, using best-matching (BM) based
methods: average (Eq. 1), maximum (Eq. 2), or complete
(Eq. 3). For a term in the annotation profile of one SNP,
all these BM-based methods calculate the maximum simi-
larity to any term in the profile of the other SNP. It can be
deduced from the formula that the average and maximum
methods are more sensitive to the number of terms than
the complete method. However, due to the current sparse
nature of EFO-based annotation of GWAS SNPs, using
any of the three methods produces similar results. Indeed,
they are interchangeable, although results from the
average and maximum methods are more similar to each
other than to the complete method (Additional file 5). By
default, the complete method is used to minimise the im-
pact of the number of terms. The resulting SNP semantic
similarity network is a weighted undirected graph, with
SNPs as nodes and semantic similarity scores as the edge
weights. Inclusion of LD SNPs is also possible for similar-
ity analysis.
Basis of SNP similarity
The function ‘xCircos’ displays the similarity results
using a circos plot, in which the degree of similarity
between two SNPs is indicated by the coloured link.
This function can be used to display the most similar
links, or those links involving a specific SNP only.
Two functions, ‘xSocialiserDAGplot’ and ‘xSocialiser-
DAGplotAdv’, are specially designed to explore the
basis of similarity seen in the circos plot. The func-
tion ‘xSocialiserDAGplot’ is used to visualise the
ontology annotation profile for an SNP, i.e. as a DAG
plot of terms used to annotate the SNP, including ori-
ginal annotations (rectangular nodes) and inherited
annotations (elliptical nodes). The function ‘xSociali-
serDAGplotAdv’ uses a DAG plot to compare annota-
tion profiles between two similar SNPs.














































where T1 is a set of n1 EFO terms used to annotate S1,
T2 is a set of n2 EFO terms annotating S2, MICA(t1, t2)
is the IC of the MICA of two terms t1 and t2, operators
MAX, MIN, and U denote, respectively, maximum, mini-
mum, and union.
Network analysis
Network analysis (or ‘Networker’) identifies the subset
(gene subnetwork) from a gene interaction network with
nodes/genes labelled with significance information.
Depending on how the node/gene significance informa-
tion is provided, there are two types of network analyses
supported in XGR: gene-based network analysis and
SNP-based network analysis.
Gene-based network analysis
The node/gene information is directly provided, e.g.
differentially expressed genes with significance measured
by false discovery rate (FDR). Given a gene interaction net-
work with nodes/genes labelled with significance, the func-
tion ‘xSubneterGenes’ searches for a maximum-scoring
gene subnetwork enriched with the most significant (highly
scored) genes but allowing for a few less significant genes
as linkers (usually hubs). The search for this maximum-
scoring subnetwork is achieved via heuristically solving a
prize-collecting Steiner tree problem; this approach has
been demonstrated to be superior to other state-of-the-art
methods. If required, an iterative procedure is applied to
identify the subnetwork with a desired number of nodes/
genes. For details please refer to our previous publication
[36].
SNP-based network analysis
We extend the network analysis to the SNP level, allow-
ing node/gene information to be indirectly provided (i.e.
derived from the input), e.g. via GWAS SNPs along with
p values. The function ‘xSubneterSNPs’ is designed to
identify a gene subnetwork that is likely modulated by
input SNPs and/or their LD SNPs. It consists of three
steps (Fig. 3a):
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1. SNP scoring (Eq. 4), which considers the p values,
the threshold (e.g. 5e-8 for typical GWAS), and
(for LD SNPs) LD strength R2.
2. Gene scoring (Eq. 5), which scores genes based
on genomic proximity to quantify their genetic
modulation by SNPs (and LD SNPs).
3. Network scoring, using the function
‘xSubneterGenes’ to identify a maximum-scoring
gene subnetwork (with the desired number of nodes
if required).








where PSNP is the SNP p value, Pthresh is the significance
threshold (usually 5e-8), and R2 is the LD strength.
Scoregene ¼ MAX
SNP∈Ω






where ScoreSNP is the SNP score calculated using Eq. 4,
d is the gene-to-SNP distance within a maximum of the
distance window D, λ is the decay exponent controlling
the decaying influence of an SNP on a nearby gene as
the distance increases, Ω stands for collections of SNPs
(input SNPs and LD SNPs), and MAX denotes maximum
scoring scheme used here to only keep the most-
informative SNP when a large number of interdependent
SNPs are located within the same genetic region.
Other implementation issues
Control for multiple testing
Where a large number of tests are involved, we adjust
p values either controlling the FDR (by default) or
controlling the family-wise error rate (FWER). FDR is
a less stringent condition than FWER. The user can
choose how to account for multiple testing.
R package dependency
We rely on the package ‘ggplot2’ [37] for various visuals
and adapt the package ‘RCircos’ [38] for a circos plot.
Where necessary for high-performance parallel compu-
ting, two packages, ‘doMC’ and ‘foreach’, are used to
reduce computational costs. Other dependent packages
are listed in [25].
A
B C
Fig. 3 Informativeness of using cross-disease GWAS summary data in characterising relationships between immunological disorders. a Gene
scoring from GWAS SNPs prior to network analysis. b Heatmap of cross-disease gene scores for 11 common immunological disorders based on
ImmunoBase GWAS summary data. c Consensus neighbour-joining tree based on the gene-scoring matrix resolves disease classification/taxonomy
according to the genetic and cellular basis of autoinflammation and autoimmunity. Subdivided into 1) polygenic autoinflammatory diseases with a
prominent autoinflammatory component, 2) polygenic autoimmune diseases with a prominent autoimmune component, and 3) mixed diseases
having both components. Inter-disease distance is defined as the cumulative difference in gene scores
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Web-app implementation
We use a next-generation Perl web framework
‘Mojolicious’ [39], under which the XGR web-app is
portable requiring nearly zero-effort maintenance. Its
maintenance is further simplified as the web-app is purely
powered by the XGR R package (stably deposited into the
CRAN repository).
Results
We demonstrate the application of XGR to interpret three
commonly encountered types of genomic summary data:
1) gene sets resulting from differential expression studies;
2) GWAS SNPs from GWAS summary data; and 3) eQTL
SNPs from eQTL summary data. We first illustrate the
functionalities supported in XGR to interpret differentially
expressed genes induced by innate immune stimuli [24].
At the SNP level, we showcase the analytical power of
XGR to interpret GWAS SNPs associated with immuno-
logical disorders [4] and to interpret eQTL SNPs relevant
to immune-stimulated systems [24]. Within these show-
cases, we demonstrate improved performance compared
to conventional analyses. All these comparisons and
showcases are provided on the software website and are
reproducible following step-by-step instructions [31].
Interpreting summary data resulting from differential
expression studies
This demo illustrates the power of XGR to interpret the
output from differential expression studies, with the
focus on how to carry out ontology-based enrichment
analysis to achieve more informative results.
Necessity of respecting the ontology tree structure when
using structured ontologies for enrichment analysis
We use Disease Ontology (DO) to interpret differentially
expressed genes induced by 24-h interferon (IFN)-γ
treatment of primary human monocytes [24]. Figure 2a
shows side-by-side comparison of enrichment results
with and without consideration of the ontology tree
structure. As expected, both analyses identify a significant
link between IFN-γ-induced transcriptome changes and
genes involved in viral infectious disease (e.g. influenza
and measles) and autoimmunity (e.g. Graves’ disease).
However, considering the ontology tree structure allows
exclusion of significant but less informative DO terms
such as ‘disease by infectious agent’. This becomes clearer
when visualising enriched terms in the context of the DO
hierarchy (Fig. 2b), showing that the child term ‘viral
infectious disease’ is a much more precise descriptor.
Necessity of filtering redundant terms when using
non-structured ontologies for enrichment analysis
When using non-structured ontologies such as a collec-
tion of pathways, we develop a post-enrichment filtering
procedure to identify redundant terms for removal
(Fig. 2c). The goal is to filter out only pathways that have
been covered by a more significant pathway of similar
granularity (scenario 2 in Fig. 2d). However, if a pathway
is informative in capturing specific knowledge and the
more significant pathway is very general, XGR will retain
it (scenario 3 in Fig. 2d). This ensures the resulting
enrichments are non-redundant but still informative
enough to help interpretation.
Interpreting GWAS summary data
This demo showcases the power of XGR to interpret
GWAS SNPs, including network and annotation analysis.
SNP-modulated genes and their informativeness for
characterising disease relationships
Unique to XGR is its ability to identify SNP-modulated
gene networks. To do this, XGR first defines and scores
genes that are likely under the genetic influence of GWAS
SNPs (Fig. 3a). When applied to GWAS summary data for
11 common immunological diseases (available from
ImmunoBase [4]), we find that genes scored in this way
(Fig. 3b) are able to resolve disease taxonomy, providing
independent evidence for a proposed continuum of
autoinflammation and autoimmunity [40]. As seen in the
consensus neighbour-joining tree (Fig. 3c), the diseases ana-
lysed span an autoinflammatory–autoimmune spectrum,
reflecting the relative roles of the innate immune
response versus the adaptive immune response in dis-
ease development. The diseases analysed are divided
into three categories: 1) polygenic autoinflammatory
diseases with a prominent autoinflammatory compo-
nent, including inflammatory bowel disease (IBD),
Crohn’s disease (CRO), and ulcerative colitis (UC); 2)
polygenic autoimmune diseases with a prominent
autoimmune component, including celiac disease
(CEL), autoimmune thyroid disease (ATD), type 1 dia-
betes (T1D), rheumatoid arthritis (RA), multiple sclerosis
(MS), and systemic lupus erythematosus (SLE); and 3)
mixed diseases having both components, including psoria-
sis (PSO) and ankylosing spondylitis (AS). Our analysis
also shows that polygenic autoinflammatory diseases may
be subdivided into two subtypes, one comprising SLE and
ATD, the other CEL, MS, T1D, and RA.
SNP-modulated gene networks underlying disease categories
To understand the molecular basis of the observed auto-
inflammatory–autoimmune disease continuum, we next
identify the top SNP-modulated gene networks based on
pooled GWAS SNPs for each of the three categories
(Fig. 4a). The gene networks identified contain hallmark
genes for each category, for example, PTPN22 and MHC
genes for polygenic autoimmune diseases and NOD2 for
polygenic autoinflammatory diseases. Comparing network
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genes identifies one gene, STAT3, common to all three
categories; a few genes, including TNFSF1A, TNIP1, and
two interleukin (IL) genes (IL23R and IL2RA) are shared
by two categories, and many genes are unique to one
group, suggesting that each disease category has its own




Fig. 4 SNP-modulated gene networks underlying three immunological disease categories. a The top-scoring gene network for the three disease
categories: autoinflammatory diseases (orange), mixed diseases (cyan), and autoimmune diseases (red). b Network genes shared by and unique to
disease categories. Genes involved in the Jak-STAT signalling pathway are in bold text. c Pathway enrichment analysis of network genes using all
pathway ontologies and eliminating redundant pathways. The horizontal dotted line separates pathways common to all three disease categories
(top section; e.g. Jak-STAT signalling pathway), those shared by any two categories (middle), and those only enriched in one category (bottom)
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pathway level we find much more commonality between
categories (Fig. 4c). For instance, all groups share the
Jak-STAT signalling pathway. In addition to the gene
STAT3, each category has unique players in this path-
way, including IL2, IFNG, IFNGR2, IL10, JAK2, and
SOCS1 in the polygenic autoinflammatory disease
gene network, IFNLR1, IL12B, IL13, IL23A, IL4, IL6R,
STAT2, and TYK2 in the mixed disease gene network,
and IL21 and STAT4 in the autoimmune gene network.
The IL12-mediated signalling pathway is another pathway
shared by all. These results suggest that targeting different
members of the same pathway for treatment might be a
useful approach. Among pathways shared by any two
groups, we find the IL pathways are informative for shared
disease features: the IL23 and IL27 pathways are common
to both autoinflammatory and mixed diseases, while the
IL2 pathway is common to both autoinflammatory and
autoimmune diseases.
Functional and phenotypic annotation of genes harbouring
GWAS SNPs for each of three disease categories
We use annotation analysis to interpret pooled GWAS
SNPs for each of the three categories by looking directly
at genes harbouring these SNPs. Here we focus on com-
monalities across two or three disease categories in
terms of functions and phenotypes shared (Fig. 5). As
shown in Fig. 5a, three disease groups share genetic
variants in genes with signal transduction activity, and
variants for both autoinflammatory and autoimmune
diseases are enriched in genes with kinase and ubiquitin
ligase binding activities. Similarly, functional commonal-
ities can be identified using GO biological processes
(Fig. 5b). Using phenotype annotations, XGR is able to
reveal shared abnormal phenotypes both in human and
mouse (Fig. 5c, d); they include diverse abnormalities
relating to inflammation and immunity, consistent with
the phenotypic complexity of these common disease
categories.
Genetic and epigenetic characterisation of GWAS SNPs for
each of three disease categories
Using functional genomic annotations supported in XGR,
we are also able to compare and define characteristics
underlying each of the three categories (Fig. 6). As a proof
of principle, we use cell type-specific genetic and epigen-
etic annotations to characterise pooled GWAS SNPs per
disease category. Based on cell type-specific expressed/ac-
tive enhancers from FANTOM5 (Fig. 6a), SNPs for auto-
immune diseases tend to be co-localised with expressed
enhancers in B lineage lymphocytes, in dendritic cells (also
seen with SNPs for mixed diseases), in T cells, and in nat-
ural killer cells (also in SNPs for autoinflammatory dis-
eases). Co-localisation with expressed enhancers in
neutrophils is only seen for autoinflammatory disease
SNPs. Using genetic and epigenetic data generated in the
GM12878 lymhoblastoid cell line (Fig. 6b–d), we identify
common characteristics, including transcription factor
binding sites, histone marks, and genome segments. The
multiple layers of information revealed by XGR provide a
powerful tool to characterise genomic features underlying
disease categories.
Interpreting eQTL summary data
This demo highlights the power of XGR to interpret
eQTL SNPs, including enrichment and similarity analysis.
Performance comparisons between conventional enrichment
analysis and ontology-based enrichment analysis
Conventionally, SNP-based enrichment analysis is only
done using traits originally reported in GWAS. However,
GWAS traits can be mapped onto EFO, enabling us to
look at general terms (representing a group of related
traits) and to include more annotated SNPs: GWAS-
reported SNPs (‘original annotations’) and inherited
SNPs from its child terms (‘inherited annotations’). By
convention, SNP-based enrichment analysis considers
LD SNPs. The benefit of using EFO and justification of
our ontology tree-aware enrichment analysis is demon-
strated using the disease part of EFO to interpret cis-eQTLs
induced by 24-h IFN-γ treatment of human monocytes
(Fig. 7a). We consider three scenarios: 1) ‘EFO (-)’ not using
EFO (i.e. conventional analysis); 2) ‘EFO (+) & Tree (-)’
using EFO but without respecting the ontology tree; and 3)
‘EFO (+) & Tree (+)’ using EFO and also respecting the
ontology tree. Using EFO identifies disease terms that
would otherwise be missed with conventional analysis.
However, without respecting the ontology tree, the redun-
dant disease terms identified would become a burden for
interpretation. Compared to conventional analysis, our
ontology tree-aware analysis identifies an additional term
(‘immune system disease’) that summarises the overall en-
richments, illustrated by visualising the enrichment results
in the EFO tree (Fig. 7b).
Cross-condition comparative enrichment analysis
We previously reported context-specific induced cis-
eQTLs that were frequently enriched for disease risk loci
[24]. Using ontology tree-aware analysis, we re-interpret
these context-specific eQTLs by comparing their disease
associations. Side-by-side barplots together with tree-
like DAG plots in Fig. 8 give sufficient information
for straightforward interpretation, aiding in hypothesis
generation. Induced cis-eQTLs, whether in the naïve
state or upon immune stimulation, are consistently
overrepresented in autoinflammatory diseases (IBD, CRO
and UC) as expected, but also linked to Parkinson’s
disease (PD).
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SNP similarity analysis based on disease trait profiles
The similarity between two SNPs is calculated based
on 1) their annotation by EFO terms organised as a
DAG, 2) specificity of terms, quantified by informa-
tion content (IC) indicative of their frequency of
annotation (including both original and inherited
annotation), and 3) term–term similarity measured as
IC at the MICA of two terms. Figure 9a illustrates
the workflow and the key concepts behind SNP simi-





Fig. 5 Functional and phenotypic annotation analysis of genes harbouring GWAS SNPs for three immunological disease categories. Visualised in
aside-by-side bar plot and/or DAG plot using functional ontologies, including a GO molecular function and b GO biological process; and using
phenotype ontologies in human and mouse, including c human phenotype phenotypic abnormality, and d mammalian phenotype
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plot, showing the SNP locations, and their pairwise
similarity by coloured links. To help understand the
similarity results, DAG plots are used to visualise the
annotation profiles, with nodes coloured according to
IC and shaped according to the type of annotation. In
this toy example, SNP 1 is most similar to SNP C as
they have the same annotation profile and share the
highly informative Term.1.1.1.1. It is less similar to
SNP A, as the MICA they share is a less informative
parent term, and least similar to SNP B as the MICA
is the root term. Figure 9b shows the similarity re-
sults when exploring cis-eQTLs induced by 24-h IFN-
γ treatment. A circos plot displays the similarity
results for all cis-eQTL SNPs, which can be reduced
to display the similarity links involving a specific SNP,
in this case rs11150589 (GWAS SNP in UC). The
DAG plots clearly show why this SNP is most similar
to rs10500264 (GWAS SNP in IBD), and has greater
similarity to rs3957148 (GWAS SNP in MS) than
rs2066807 (GWAS SNP in PSO). Together with
knowledge of eQTL-containing genes such as ITGAL
cis-regulated by rs11150589 and CNPY2 by rs2066807
(Fig. 9b), disease profile-derived similarity between
SNPs adds a new dimension to eQTL mapping inter-
pretations. By identifying pairs of SNPs sharing the
similar annotation/trait profiles, this piece of informa-
tion can be used to select variants for follow-up
functional studies such as from QTL mapping. SNP
similarity measured in this way would be also useful
in predicting physical interactions between genomic
regions involving both SNPs, particularly when SNP
annotations by EFO become more complete.
Discussion
Demanding issues addressed by XGR
In the current era of high-throughput genomics, the
volume of data relating to complex human disease is





Fig. 6 Functional genomic annotation analysis of GWAS SNPs by genomic location for three immunological disease categories. a Using the FANTOM
cell type-specific expressed enhancer data, b using ENCODE ChIP-seq transcription factor binding site (TFBS) data, c using ENCODE histone mark data,
and (d) using ENCODE genome segment information. Panels b–d use genetic and epigenetic data generated in the GM12878 lymphoblastoid cell line
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GWAS Catalog contains 2546 studies at the time of
writing (October 2016) [3], and there have been many
success stories in terms of the identification of risk loci
and the discovery of disease mechanisms. However, gen-
omics has not yet nearly realised its full potential in this
regard. In general, the generation of large datasets and
their analysis through association studies are not the end
goal of disease genomics, but instead represent a starting
point for downstream interpretation, which aims to
place preliminary results in a biological context. This
post-GWAS stage benefits from the leveraging of
multiple data sources and requires a general framework
for the integration of the available knowledge and the
application of appropriate methodologies to reveal the
underlying information in a systematic way. XGR is
created to meet this emerging need.
Web-app user interface of XGR
All results described above are generated using the R
package. To target users who are unfamiliar with R, we
also develop a user-friendly web interface for each of the
analyses supported by XGR (Fig. 1). In the web-app,
users can simply paste gene or SNP lists of interest,
choose an ontology or network, and specify parameters
(or at default values). After submission, users can
A
B
Fig. 7 Necessity of using Experimental Factor Ontology and respecting ontology tree-like structure in SNP-based enrichment analysis. This is dem-
onstrated using the disease subgraph of the Experimental Factor Ontology (EFO) and analysing cis-eQTLs induced by 24-h IFN-γ. a Side-by-side
bar plots comparing the significant EFO terms between the analysis not using EFO (conventional analysis; EFO (-)) and two ontology-based ana-
lyses: the EFO (+) & Tree (-) analysis using EFO but without respecting the ontology tree, and the EFO (+) & Tree (+) analysis using EFO and also re-
specting the ontology tree. The horizontal dotted lines separate commonly identified terms (top), the terms unique to the ontology-based
analyses (middle), and the redundant terms identified by the EFO (+) & Tree (-) analysis (bottom). b DAG plot comparing terms identified by all ana-
lyses (coloured in cyan), by two analyses (coloured in light cyan), and only by one analysis (coloured in lightest cyan). The term name (if significant)
is prefixed in the form of ‘x1-x2-x3’. In this case, x1 for ‘EFO (-)’, x2 for ‘EFO (+) & Tree (-)’, x3 for ‘EFO (+) & Tree (+)’. The value of x1–3 can be ‘1’ or
‘0’, denoting whether this term is identified (present) or not (absent)
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download, search, and explore the outputs in the form
of various visuals.
Generality of analyses supported by XGR
As well as software, XGR is also a resource incorporat-
ing diverse data types, thereby enabling comprehensive
investigation of a gene or SNP set through enrichment,
network, similarity, and annotation analysis. User input
is not limited to the gene or SNP-centric data types.
XGR can also be used to analyse genomic regions
directly (Fig. 6), or indeed carry out enrichment analysis
for any entity, e.g. protein domains (as demonstrated in
the web-app). Overall, XGR is designed to be scalable,
whilst also being efficient and effective.
Uses and benefits of XGR
In the “Results” section, we demonstrate the intended
uses of XGR to interpret three commonly encountered
types of genomic summary data: gene sets resulting from
differential expression studies; GWAS SNPs from
GWAS summary data; and eQTL SNPs from eQTL
summary data. In these use cases, we explore the genetic
landscape of the immune system and immunological
disorders, using differential expression and eQTL data
A
B
Fig. 8 Comparative enrichment analysis for cis-eQTL SNPs under four immunologically relevant conditions. The four eQTL SNP sets are: naive state
(Naïve cis-eQTLs), induced by 2-h LPS (LPS2 cis-eQTLs), by 24-h LPS (LPS24 cis-eQTLs), and by 24-h IFN-γ (IFN24 cis-eQTLs). All analyses are using the
disease subgraph of EFO and respecting the ontology tree. a Side-by-side bar plots comparing the significant EFO terms across the four conditions.
The horizontal dotted lines separate terms shared by four conditions (top), by three conditions (upper middle), by two conditions (lower middle), and
unique to one condition (bottom). b DAG plot comparing the significant EFO terms across the four conditions. Nodes/terms are coloured according
to the number of conditions sharing the terms
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Fig. 9 SNP similarity analysis interpreting eQTL SNPs. a This toy example illustrates the SNP similarity analysis, which calculates pairwise semantic
similarity between SNPs using the Experimental Factor Ontology (EFO). The input is a list of SNPs, with the option to include SNPs in linkage
disequilibrium (LD). The output is a circos plot, with the link line colour graded according to the degree of semantic similarity between each
pair of SNPs. The calculation of similarity takes into account the annotation profile of the SNPs, the information content (IC) of the term, and the
term–term similarity. In our example, each SNP is directly annotated by two terms, and inherit additional annotation terms according to the
true-path rule. The terms are coloured according to their IC; original terms have a rectangular border, inherited terms an elliptical border. SNP 1
shows similarity of varying degrees to the other three SNPs based on their shared annotation profiles. SNP 1 and SNP C share both “Term 1” and
the very informative “Term 1.1.1.1”; as such, they have a very high degree of semantic similarity. SNP 1 and SNP A do not share any terms directly;
however, SNP 1’s “Term 1.1.1.1” and SNP A’s “Term 1.1.1.2” are both child terms of “Term 1.1.1” and so a similarity measure can be calculated
based on this term. “Term 1.1.1” is the most informative common ancestor (MICA) between the two SNP annotation profiles, meaning they have
a relatively high degree of similarity. The MICA of SNP 1 and SNP B is “Term 1”. Since this term is less informative than the MICA of SNP 1 and
SNP A (lower IC value), the similarity score between SNP 1 and SNP B is lower. b Semantic similarity results for real data. Global similarity output
for cis-eQTLs induced by 24-h IFN-γ is shown in the circos plot (top left). The top similarity links involving a specific SNP, rs11150589, are shown in
the main circos plot, together with DAG plots showing the terms annotating each SNP. The genes modulated by the eQTL SNPs are given
in brackets
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for stimulated monocytes and the GWAS summary data
for a dozen or so common diseases. These showcases
are intended to give an overview of the workflow and
functionality of XGR, while simultaneously showing the
benefits of XGR to uncover interesting biology in real
applications. For example, we find evidence for a link be-
tween the immune system and Parkinson’s disease when
re-interpreting context-specific eQTL (Fig. 8). This is
supported by a recent study suggesting that Parkinson’s
disease may be considered as an autoimmune disease
[41] with aging-induced changes in the immune system
a potential contributor, and highlights the need for
further work in this area. Another interesting finding is
the disease vitiligo, overrepresented in analysis of eQTL
but only involving activated monocytes; this is consistent
with the hypothesis that vitiligo is triggered by cellular
stress, danger signals, and innate immune activation
[42]. Similarity analysis adds a new dimension in inter-
preting eQTL SNPs, not just showing their relevance to
GWAS traits but also measuring how similar they are to
each other in the meaning of trait profiles (i.e. ontology
annotation profiles). Network analysis in XGR is unique
in its power to identify SNP-modulated gene networks,
defining disease subtypes based on GWAS SNPs (Fig. 3),
and revealing shared and unique features across subtypes.
The disease subtypes correspond well with the idea that
immunological disorders form a spectrum from autoin-
flammatory to autoimmune based on clinical and mech-
anistic features [40]. It is generally recognised that
pathophysiological mechanisms are shared across this
disease spectrum to a greater or lesser extent. The
analysis presented in this study, together with other
studies leveraging the informativeness of current genetic
data [7, 43, 44], helps to reveal the nature of these
relationships, illustrating how cross-disease analysis can
enhance opportunities for identifying central mediators as
potential drug targets.
Improved performance of XGR
We evaluate the performance of XGR in generating
more informative results than conventional analyses. In
particular, we show the necessity of respecting the ontol-
ogy tree-like structure during enrichment analysis, either
for genes or SNPs (Figs. 2 and 7). In the literature, the
use of ontologies has gained popularity but is largely
done without taking the structure itself into account
(thus much less effective). We also show that XGR is
able to perform cross-disease analysis. When coupled
with annotation analysis (via nearby gene annotations or
via co-localised functional genomic annotations), XGR is
able to perform in-depth interpretation of the underlying
genetic landscape of immunological diseases (Figs. 5 and 6).
Therefore, XGR provides a single integrated solution to
improve interpretation of genomic summary data for
downstream biological discovery; this can also be seen from
Table 2, which provides a comparison in terms of function-
ality and availability between XGR and other freely available
tools, such as DAVID [45], GREAT [46], DEPICT [47],
GOSemSim [48], GRAIL [49], dnet [36], and jActiveMo-
dule [50], to name but a few. This comparison also identi-
fies a need for XGR to support other uses such as
prioritisation, and to provide an online discussion/FAQ
platform as the user base increases.
Future development of XGR
We are actively engaged in, and have a long-term com-
mitment to, ensuring XGR is updated and expanded on
a regular basis (both functionality and data sources) as
the field advances. For example, the built-in data include
a number of structured ontologies, e.g. GO, DO, Human
Phenotype Ontology, and EFO. The hierarchical nature
of ontologies provides additional information concerning
the relationships between terms, which we leverage to
enhance downstream biological discovery and increase
the informativeness of the outputs generated. SNP-level
analysis supported in XGR is unique in its ontology tree-
awareness through mapping of GWAS Catalog traits to
EFO and the ability to calculate semantic similarity, but
is currently restricted to use of this single ontology. As
additional resources become available for orthogonal know-
ledge domains, these will be incorporated into XGR to ex-
pand its capacity for multi-layered investigation of genomic
summary data. Other than the data expansion, future ef-
forts will focus on increasing and enabling the user base
(including deployment to community-driven genomics pro-
jects), evaluating predictive use of SNP similarity in
chromosomal interactions (such as promoter interactomes
[51]), and extending the network analysis to the genomic
region level (such as differentially methylated regions).
Conclusions
The publicly available XGR R package and web-app
(Fig. 1) presented here provide a user-friendly, flexible,
and powerful tool for the exploration and interpretation
of genomic summary data. As the field of big data con-
tinues to expand and new resources become available,
XGR will evolve alongside as an integrated solution for
revealing underlying biological information.
Availability and requirements
Project name: XGR
Project home page (web-app): http://galahad.well.ox.-
ac.uk/XGR
R package: http://cran.r-project.org/package=XGR
Operating system(s): Linux, Mac OS X, Windows
Programming language: R
License: GNU GPL
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Additional files
Additional file 1: Comparison of three tests used for enrichment analysis.
The tests compared are hypergeometric test, Fisher’s exact test, and
binomial test. The DO enrichment analysis is applied to the same set of
genes, namely differentially expressed genes induced by IFN-γ treatment of
primary human monocytes [24]. (PDF 206 kb)
Additional file 2: Exploring the statistical test for enrichment through
null simulations. The hypergeometric test is used for DO enrichment
analysis applied to a set of genes, namely differentially expressed genes
induced by IFN-γ treatment of primary human monocytes [24], identifying
eight enriched terms (FDR <0.05). To estimate the chance of these enriched
terms resulting from the real data that would be expected from a null
distribution, we simulate a random set of genes (having the same number
of genes as in the real data) for 10,000 times. Applying DO enrichment
analysis to the simulated data, we count how often each enriched term is
called significant under FDR <0.05. We also count how often each enriched
term is called significant from the simulated data, but under the same or
lower term-specific FDR (for example, 3.10E-05 for the term ‘viral infectious
disease’). (PDF 58 kb)
Additional file 3: Estimating false positive rate for enrichments of genes
of different sizes through null simulations. We use DGIdb gene druggable
categories [30] for this purpose; there are a total of ~30 gene categories
(thus computationally feasible), with gene members of different sizes. For
each category, we simulate a random set of genes (having the same
number as genes annotated by this category) for 20,000 times, and
estimate how often (false positive rate) this category would be identified
as enrichment (under different FDR cutoffs: <1E-1, <5E-2, <1E-2 and <5E-
3) from the simulated data. a Histogram plot of FDR calculated from the
simulated data, using the term ‘Tumor suppressor’ as an exemplar. b Dot
plot of false positive rate (on the x-axis) for gene categories (ordered by
the size of gene members on the y-axis). (PDF 565 kb)
Additional file 4: Justification of the 90 and 50% criteria used to remove
redundant terms resulting from enrichment analysis. The pathway
enrichment analysis is applied to the same set of genes (that is, differentially
expressed genes induced by IFN-γ treatment of primary human monocytes
[24]). a >90% of members in a redundant term that overlap with members in
a more significant term. b >50% of members in a more significant term that
overlap with members in a redundant term. (PDF 234 kb)
Additional file 5: Correlations of SNP similarity using best-matching
(BM)-based methods. BM methods compared are average (BM.average),
maximum (BM.max), and complete (BM.complete). SNP similarity analysis
is applied to the same set of SNPs (cis-eQTLs) induced by IFN-γ treatment
of primary human monocytes [24]. (PDF 129 kb)
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AS: Ankylosing spondylitis; ATD: Autoimmune thyroid disease; BM: Best-
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